Hepatobiliary scintigraphy using sup(99m)Tc-(Sn)-pyridoxylideneisoleucine for the diagnosis of the diffuse liver disease

94 cases of hepatobiliary scintigram using sup(99m)Tc-(Sn)-Pyridoxylideneisoleucine (PI) were reviewed. The cases comprised 19 liver cirrhosis, 22 chronic hepatitis, 7 acute hepatitis, 3 fatty liver and 11 controls without hepatobiliary disease. The uptake and excretion of sup(99m)Tc-(Sn)-PI in the regions of interest (ROI) set up on the liver and gallbladder were recorded by a scintillation camera and a digital printer. Ratio of the radioactivity in the ROI at 15, 30, 45 minutes after sup(99m)Tc-(Sn)-PI injection to the radioactivity in the ROI at 5 minutes after sup(99m)Tc-(Sn)-PI injection were calculated and compared among various diffuse liver disease and controls. The highest ratio was obtained in control group, and then in the cases of fatty liver, chronic hepatitis, liver cirrhosis, and acute hepatitis in that order. This ratio and serum-alkaliphosphatase were well correlated. (author)